Health Care [ 4/12 ] | Biotechnology [ 18/75 ]
NASDAQ | Common Stock
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.
The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck.
It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3.
The company was founded in 2007 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 19, 26 | 0.00 Increased by +100.00% | -0.30 Increased by +100.00% |
| Nov 13, 25 | -0.27 Decreased by -22.73% | -0.27 Increased by +1.21% |
| Aug 7, 25 | -0.32 Increased by +27.27% | -0.26 Decreased by -23.08% |
| May 12, 25 | -0.26 Increased by +45.83% | -0.29 Increased by +11.35% |
| Mar 24, 25 | -0.30 Increased by +46.49% | -0.38 Increased by +21.05% |
| Nov 7, 24 | -0.22 Increased by +68.57% | -0.36 Increased by +38.89% |
| Aug 8, 24 | -0.44 Increased by +41.33% | -0.44 |
| May 14, 24 | -0.48 Increased by +17.24% | -0.54 Increased by +11.11% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 2.00 M Increased by +N/A% | -9.78 M Increased by +34.26% | Decreased by -489.20% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by -100.00% | -15.78 M Decreased by -49.05% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -18.71 M Increased by +11.20% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -15.33 M Increased by +34.00% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -14.88 M Increased by +44.72% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 11.00 M Increased by +N/A% | -10.59 M Increased by +68.23% | Decreased by -96.24% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -21.07 M Increased by +41.06% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -23.23 M Increased by +15.39% | Decreased by N/A% Decreased by N/A% |